-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Comparison of BUMEL and MEL200 in ASCT in patients previously treated with bortezomib, lenalidomide and dexamethasone in NDMM patients most of the data on myeloablative pretreatment protocols were based on data registries, observational studies, clinical experience, and Phase I/II clinical trials
Figure 1
Of the 458 initial patients, 396 received ASCT (BUMEL n=202, MEL200 n=194).
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
References:
1.
2.
Edit: Moly Reviewer: Mia Typography: Moly Executive: Wenting
Poke "Read the original article" to see more